gp130 AND THE INTERLEUKIN-6 FAMILY OF CYTOKINES

Article Properties
  • Language
    English
  • Publication Date
    1997/04/01
  • Indian UGC (Journal)
  • Refrences
    130
  • Citations
    1,059
  • Tetsuya Taga Institute for Molecular and Cellular Biology, Osaka University, 1-3 Yamada-oka, Suita, Osaka 565, Japan;Present address: Department of Molecular Cell Biology, Medical Research Institute, Tokyo Medical and Dental University, 2-3-10 Kanda-Surugadai, Chiyoda-Ku, Tokyo 101, Japan
  • Tadamitsu Kishimoto Department of Medicine III, Osaka University Medical School, 2-2 Yamada-oka, Suita, Osaka 565, Japan
Abstract
Cite
Taga, Tetsuya, and Tadamitsu Kishimoto. “gp130 AND THE INTERLEUKIN-6 FAMILY OF CYTOKINES”. Annual Review of Immunology, vol. 15, no. 1, 1997, pp. 797-19, https://doi.org/10.1146/annurev.immunol.15.1.797.
Taga, T., & Kishimoto, T. (1997). gp130 AND THE INTERLEUKIN-6 FAMILY OF CYTOKINES. Annual Review of Immunology, 15(1), 797-819. https://doi.org/10.1146/annurev.immunol.15.1.797
Taga T, Kishimoto T. gp130 AND THE INTERLEUKIN-6 FAMILY OF CYTOKINES. Annual Review of Immunology. 1997;15(1):797-819.
Journal Categories
Medicine
Internal medicine
Specialties of internal medicine
Immunologic diseases
Allergy
Description

How does gp130 mediate the diverse effects of the interleukin-6 family of cytokines? This review examines the role of gp130, a common signal-transducing receptor component, in mediating the biological functions of the interleukin-6 family of cytokines. Understanding these signaling pathways is crucial for comprehending immune and hematopoietic regulation. The review discusses how receptors for interleukins and cytokines in the class I cytokine receptor family form multichain complexes. The interleukin-6 family of cytokines, including interleukin-6, interleukin-11, and leukemia inhibitory factor, all share gp130 as a critical component for signal transduction. Stimulation of cells with these cytokines triggers homo- or heterodimerization of gp130, leading to activation of cytoplasmic tyrosine kinases and subsequent modification of transcription factors. This paper provides a comprehensive overview of recent advances in understanding the interleukin-6 family of cytokines and gp130 signaling. Further research could explore the therapeutic potential of targeting these pathways in various diseases.

Published in the Annual Review of Immunology, this research aligns perfectly with the journal's focus on immunology and cytokine biology. The study's detailed examination of gp130 and its role in interleukin-6 signaling directly contributes to the journal's core themes.

Refrences
Citations
Citations Analysis
The first research to cite this article was titled A New Type of Cytokine Receptor Antagonist Directly Targeting gp130 and was published in 1998. The most recent citation comes from a 2024 study titled A New Type of Cytokine Receptor Antagonist Directly Targeting gp130 . This article reached its peak citation in 2000 , with 69 citations.It has been cited in 468 different journals, 14% of which are open access. Among related journals, the Journal of Biological Chemistry cited this research the most, with 58 citations. The chart below illustrates the annual citation trends for this article.
Citations used this article by year